U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.
about
Post-exposure prophylaxis for SIV revisited: animal model for HIV preventionAntiretroviral Therapy and Pregnancy Outcomes in Developing Countries: A Systematic ReviewThe renaissance of fixed dose combinations: CombivirTransplacental exposure to AZT induces adverse neurochemical and behavioral effects in a mouse model: protection by L-acetylcarnitine.Improving outcomes in infants of HIV-infected women in a developing country settingEvaluation of Medication-mediated Effects in Pharmacoepidemiology.Prevention of vertical HIV transmission and management of the HIV-exposed infant in Canada in 2014The second generation of HIV-1 vertically exposed infants: a case series from the Italian Register for paediatric HIV infectionMother-to-child transmission of HIV: experience at a referral hospital in Saudi Arabia.Antiretroviral Therapy Containing Raltegravir to Prevent Mother-to-Child Transmission of HIV in Infected Pregnant WomenDifferential bidirectional transfer of indinavir in the isolated perfused human placenta.Placental transfer of darunavir in an ex vivo human cotyledon perfusion model.Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCsEarly initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood.The effect of prophylaxis on pediatric HIV costsDrug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIVMode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe.Update on the Epidemiology and Prevention of HIV/AIDS in the United States.Group motivational interviewing to promote adherence to antiretroviral medications and risk reduction behaviors in HIV infected women.Preconception care for improving perinatal outcomes: the time to actChildbirth Education for the HIV-Positive WomanSalvage Regimens Containing Darunavir, Etravirine, Raltegravir, or Enfuvirtide in Highly Treatment-Experienced Perinatally Infected Pregnant Women.The 30-year war on AIDS: have we reached the tipping point?Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.Natural Conception May Be an Acceptable Option in HIV-Serodiscordant Couples in Resource Limited Settings.Complications of cesarean deliveries among HIV-infected women in the United States.Evaluation of Hepatic Mitochondria and Hematological Parameters in Zidovudine-Treated B6C3F(1) Mice.Effect of pregnancy on emtricitabine pharmacokinetics.Mode of delivery and neonatal respiratory morbidity among HIV-exposed newborns in Latin America and the Caribbean: NISDI Perinatal-LILAC Studies.Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma.Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: the impact of social network factors, side effects, and perceived treatment efficacyFetal cord blood mononuclear cells that are collected at term from HIV-1 infected women harbor transcriptionally active integrated proviral DNA.Benefits of PrEP as an Adjunctive Method of HIV Prevention During Attempted Conception Between HIV-uninfected Women and HIV-infected Male Partners.Thirty years later: pregnancies in females perinatally infected with human immunodeficiency virus-1.Laboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025Pharmacokinetics of tenofovir during pregnancy and postpartum.Missed opportunities for prevention of mother-to-child transmission of HIV-1 in the NISDI Perinatal and LILAC cohorts.Integrase inhibitors in late pregnancy and rapid HIV viral load reduction.Postoperative infectious morbidities of cesarean delivery in human immunodeficiency virus-infected women
P2860
Q21245029-837C2074-B29C-4DA9-A660-B4D37FF356ADQ28080543-64B8F6AC-3780-4407-84ED-CA02A8D82C17Q28279752-A83343B6-D8CC-472A-A7D3-72056FF36006Q28486041-F7C10CF6-8A88-44AF-9C96-6C35C10D89C0Q33384449-CD170F3D-418A-4A31-A79D-22CCF91971F4Q33557870-D75A8A64-E87E-48AD-B5BA-C903E5B571CAQ33640210-136D43B3-3D88-4ABB-A12B-AC08359E3E32Q33673661-6B5A1749-034F-41A3-B7AA-4296E4C4F6F8Q33772085-E9F029D5-C812-47F5-AFAB-CB03696788C3Q33815637-7CD55284-31C4-4C25-AEEA-EC543108444CQ33857508-D6154BCE-C446-4A95-94A7-9FD676682765Q34057304-CCF76C83-9593-4789-9749-71D4963528AFQ34085343-0C7F0463-54FF-4748-9222-D24AAB8F2968Q34285730-C3C17DB6-B328-44E7-845D-1B6F7838EF98Q34359917-02740104-F39A-4686-9516-DDEC58416E31Q34538556-814A2D04-3E67-4963-B649-16C8B4391995Q34615517-A6435940-50AA-4934-BBA5-BB392DA7DC24Q34669756-F89C30CE-9888-49A6-830E-6385C59BD421Q35038111-524542D7-3E53-41D1-AE32-6ACBF08C1538Q35069618-A40470CB-6186-4CD7-8165-E7CECFD71B7CQ35074618-4760C771-6618-47D1-893E-0A4029C0E959Q35239273-3536DB9C-D2F4-454C-9619-E6B74733C8F7Q35580656-F774DA4A-DA71-474A-9816-DC6EFC7A4396Q35659264-A0D2B532-1050-451D-B30A-A7E9EE9C7757Q35827891-483D9547-71CC-4B88-9572-E55D8FF8D30DQ35833382-67B848EE-4A06-40EA-AD98-D2021746B637Q35874984-CD8FA345-8B84-43EF-8F4C-9AA3014A4AA3Q35875962-B78038DF-E3A6-424B-8FD3-D2618170DD88Q35930696-E8B61BA1-69A0-4CDF-8880-A3E1F40262A6Q36011836-D3A782AB-8966-4EB8-AEB2-EA16BD20158DQ36025069-41E26C11-1F0B-40AB-884A-7C2671982C0AQ36031436-2F9FAB7A-4A31-4010-9E86-6967E8D29FCBQ36177530-30F6ACD7-B89F-4D10-9749-F9B6784D414FQ36208647-8DDCC0B5-A656-4B75-8854-2A0EAE7E8ACEQ36210517-212D1DF4-0068-49A6-AEA0-41D3476428BBQ36851168-D1FD12EB-DD2C-4E83-B2BA-D53FD251C184Q36888597-DAB307AB-BD9F-4D5C-A613-A5E8ADA18EFDQ36931935-F180129C-B906-4C01-85A6-57F86FAE70FBQ37199763-873739C5-5875-4910-9233-9EFA235D1F22Q37201742-87556353-A2FF-4F83-89B5-EAF968DD87CE
P2860
U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
U.S. Public Health Service Tas ...... smission in the United States.
@ast
U.S. Public Health Service Tas ...... smission in the United States.
@en
type
label
U.S. Public Health Service Tas ...... smission in the United States.
@ast
U.S. Public Health Service Tas ...... smission in the United States.
@en
prefLabel
U.S. Public Health Service Tas ...... smission in the United States.
@ast
U.S. Public Health Service Tas ...... smission in the United States.
@en
P921
P1476
U.S. Public Health Service Tas ...... smission in the United States.
@en
P2093
Centers for Disease Control and Prevention, U.S. Public Health Service Task Force
Lynne M Mofenson
P304
1-38; quiz CE1-4
P577
2002-11-01T00:00:00Z